peptidylprolyl isomerase A pseudogene 35Genealiases: []
Q-omics provides the consensus-scored PPIAP35 profile across patient tissues and cancer cell-line models. PPIAP35 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, PPIAP35 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, PPIAP35 RNA expression shows 11,220 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KICH, COAD, and ACC as cancer lineages where PPIAP35 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPIAP35 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPIAP35 survival associations across molecular data types. PPIAP35 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPIAP35 RNA expression–survival associations across cancer types. High PPIAP35 expression shows unfavorable associations in KICH, LIHC, ACC, KIRP and MESO, but favorable associations in BLCA. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KICH as the clearest survival context for PPIAP35 RNA expression.
This table summarizes PPIAP35 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for PPIAP35. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPIAP35 shows higher tumor expression in COAD, HNSC, LUAD, BLCA, LUSC and LIHC. The COAD box plot shows higher PPIAP35 RNA expression in tumor versus normal tissue (log2 FC = +0.305, t-test p < 0.001).
This table shows molecular features associated with PPIAP35 in patient tissues and cancer cell lines. In patient samples, PPIAP35 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
